Related Experiment Video
Updated: Dec 23, 2025
08:04
Preparation of Functional Silica Using a Bioinspired Method
Published on: August 1, 2018
17.7K
Nanoarchitectured Structure and Surface Biofunctionality of Mesoporous Silica Nanoparticles
Ranjith Kumar Kankala1, Ya-Hui Han1, Jongbeom Na2,3
1College of Chemical Engineering, Institute of Biomaterials and Tissue Engineering, Fujian Provincial Key Laboratory of Biochemical Technology, Huaqiao University, Xiamen, 361021, P. R. China.
Advanced Materials (Deerfield Beach, Fla.)
|April 23, 2020
Summary
Mesoporous silica nanoparticles (MSNs) show promise in medicine due to their unique structure. Modifications enhance their properties for advanced drug delivery and therapeutic applications.
Area of Science:
- Materials Science
- Nanotechnology
- Biomedical Engineering
Background:
- Mesoporous silica nanoparticles (MSNs) possess attractive physicochemical and morphological properties.
- MSNs are utilized in adsorption, catalysis, and medicine.
- Pristine MSNs face limitations in drug loading, compatibility, and degradability for biomedical uses.
Purpose of the Study:
- To provide an overview of MSN fabrication and engineering advancements.
- To discuss structural and physicochemical attribute modifications of MSNs.
- To emphasize the impact of these advancements on biomedical applications.
Main Methods:
- Overview of MSN fabrication techniques.
- Discussion of surface modification strategies for MSNs.
- Analysis of recent studies on engineered MSNs for biomedical applications.
Main Results:
- Engineered MSNs exhibit improved drug loading, compatibility, and degradability.
- Surface modifications with supramolecular assemblies and metal species enhance MSN functionality.
- Advanced MSNs demonstrate potential in stimuli-responsive drug delivery and in vivo therapies.
Conclusions:
- Engineered MSNs offer enhanced properties for biomedical applications.
- Substantial advancements facilitate innovative therapeutic and diagnostic uses.
- Further research and development are crucial for clinical translation of MSNs.
